Core Viewpoint - Ventyx Biosciences, Inc. reported its second quarter financial results and highlighted advancements in its clinical pipeline, focusing on innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases [1] Pipeline Updates and Anticipated Milestones - The Phase 2 trial of VTX2735 for recurrent pericarditis is ongoing, with expectations to release topline results in Q4 2025 [2][4] - VTX3232 has completed enrollment in a Phase 2 study for obese participants with cardiometabolic risk factors, with topline results anticipated in early Q4 2025 [2][6] - Positive Phase 2a data for VTX3232 in early-stage Parkinson's disease demonstrated safety, tolerability, and significant biomarker suppression, leading to plans for further clinical trials [3][5] Financial Results - As of June 30, 2025, Ventyx reported cash, cash equivalents, and marketable securities totaling $209.0 million, sufficient to fund operations into at least H2 2026 [5][9] - Research and Development (R&D) expenses for Q2 2025 were $22.3 million, down from $27.8 million in Q2 2024, while General and Administrative (G&A) expenses decreased to $7.1 million from $7.9 million [11][17] - The net loss for Q2 2025 was $27.0 million, compared to a net loss of $32.0 million in Q2 2024 [11][17] Inflammatory Bowel Disease (IBD) Portfolio - Ventyx is exploring development options for VTX958 in Crohn's disease, including potential partnerships [8][12] - Tamuzimod (VTX002) has shown promising Phase 2 induction data in ulcerative colitis, indicating potential for combination therapies [11][12]